ATE178207T1 - Verwendung von 2-(2-nitro-4- trifluormethylbenzoyl)-1,3-cyclohexandion zur behandlung von tyrosinämie sowie pharmazeutische zusammensetzungen - Google Patents

Verwendung von 2-(2-nitro-4- trifluormethylbenzoyl)-1,3-cyclohexandion zur behandlung von tyrosinämie sowie pharmazeutische zusammensetzungen

Info

Publication number
ATE178207T1
ATE178207T1 AT92912215T AT92912215T ATE178207T1 AT E178207 T1 ATE178207 T1 AT E178207T1 AT 92912215 T AT92912215 T AT 92912215T AT 92912215 T AT92912215 T AT 92912215T AT E178207 T1 ATE178207 T1 AT E178207T1
Authority
AT
Austria
Prior art keywords
pharmaceutical compositions
tyrosinemia
trifluormethylbenzoyl
cyclohexandione
nitro
Prior art date
Application number
AT92912215T
Other languages
English (en)
Inventor
Martin Keith Ellis
Sven Torvald Lindstedt
Edward Alan Lock
Maj Elisabeth Markstedt
Linda Carol Mutter
Michael Paul Prisbylla
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB919113622A external-priority patent/GB9113622D0/en
Priority claimed from GB929206412A external-priority patent/GB9206412D0/en
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Application granted granted Critical
Publication of ATE178207T1 publication Critical patent/ATE178207T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Hydrogenated Pyridines (AREA)
AT92912215T 1991-06-24 1992-06-18 Verwendung von 2-(2-nitro-4- trifluormethylbenzoyl)-1,3-cyclohexandion zur behandlung von tyrosinämie sowie pharmazeutische zusammensetzungen ATE178207T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919113622A GB9113622D0 (en) 1991-06-24 1991-06-24 Medicinal agents
GB929206412A GB9206412D0 (en) 1992-03-24 1992-03-24 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
ATE178207T1 true ATE178207T1 (de) 1999-04-15

Family

ID=26299120

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92912215T ATE178207T1 (de) 1991-06-24 1992-06-18 Verwendung von 2-(2-nitro-4- trifluormethylbenzoyl)-1,3-cyclohexandion zur behandlung von tyrosinämie sowie pharmazeutische zusammensetzungen

Country Status (16)

Country Link
US (1) US5550165A (de)
EP (1) EP0591275B1 (de)
JP (1) JP3130935B2 (de)
AT (1) ATE178207T1 (de)
AU (1) AU672361B2 (de)
CA (1) CA2072047C (de)
DE (2) DE69228813T2 (de)
DK (1) DK0591275T3 (de)
ES (1) ES2129448T3 (de)
GR (1) GR3029841T3 (de)
IE (1) IE922024A1 (de)
LU (1) LU91180I2 (de)
NL (1) NL300198I2 (de)
NO (3) NO304923B1 (de)
PT (1) PT100619B (de)
WO (1) WO1993000080A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4305696A1 (de) * 1993-02-25 1994-09-01 Hoechst Ag Nachweisverfahren zur Identifizierung von Inhibitoren
AU5116099A (en) * 1998-07-21 2000-02-14 Sui Xiong Cai Novel fluorescence dyes and their applications for whole cell fluorescence screening assays for caspases, peptidases, proteases and other enzymes and the use thereof
GB0504103D0 (en) * 2005-02-28 2005-04-06 Syngenta Ltd Novel method
CA2659424A1 (en) * 2006-08-18 2008-02-21 Syngenta Limited Use of hppd inhibitors in the treatment of depression and/or withdrawal symptoms associated with addictive drugs
JP5867081B2 (ja) * 2010-01-29 2016-02-24 東レ株式会社 胆道疾患の治療又は予防剤
RS54632B1 (sr) * 2011-06-23 2016-08-31 Swedish Orphan Biovitrum International Ab Tečna farmaceutska kompozicija koja sadrži nitizinon
WO2013181292A1 (en) * 2012-05-29 2013-12-05 Biotie Therapies, Inc. Nitisinone formulations
CN102976948B (zh) * 2012-11-28 2014-07-09 郑州大明药物科技有限公司 尼替西农的制备方法
GB201400117D0 (en) 2014-01-03 2014-02-19 Cycle Pharmaceuticals Ltd Pharmaceutical composition
ITUB20160650A1 (it) * 2016-02-11 2017-08-11 Dipharma S A Formulazioni farmaceutiche solide stabili contenenti 2-(2-nitro-4-trifluorometilbenzoil)-1,3-cicloesandione
US9783485B1 (en) 2016-11-30 2017-10-10 Dipharma S.A. Crystalline inhibitor of 4-hydroxyphenylpyruvate dioxygenase, and a process of synthesis and crystallization thereof
EP3888684A1 (de) * 2020-03-31 2021-10-06 Bayer Animal Health GmbH Zusammensetzung mit verbesserter freiwilliger akzeptanz
CN112460914A (zh) * 2020-11-01 2021-03-09 江苏珠合新能源科技有限公司 一种干冰机尾气冷量回收调节工艺装置
WO2024047657A1 (en) * 2022-08-28 2024-03-07 Brawn Laboratories Ltd Process for the preparation of nitisinone

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4780127A (en) * 1982-03-25 1988-10-25 Stauffer Chemical Company Certain 2-(substituted benzoyl)-1,3-cyclohexanediones and their use as herbicides
IL77349A (en) * 1984-12-20 1990-07-12 Stauffer Chemical Co 2-(2'-nitrobenzoyl)-1,3-cyclohexanediones,their preparation and their use as herbicides
US4774360A (en) 1987-06-29 1988-09-27 Stauffer Chemical Company Converting enol ester precursor of a benzoyl-1,3-cycloalkyldione to a benzoyl-1,3-cycloalkyldione
US4859234A (en) 1987-09-14 1989-08-22 Ici Americas Inc. Herbicidal compositions of acylated 1,3-dicarbonyl herbicides and phenoxyalkanoic acids, salts, amides and esters therof as antidotes

Also Published As

Publication number Publication date
NL300198I2 (nl) 2005-09-01
DE69228813T2 (de) 1999-08-05
NO304923B1 (no) 1999-03-08
US5550165A (en) 1996-08-27
EP0591275B1 (de) 1999-03-31
CA2072047A1 (en) 1992-12-25
DE122005000032I2 (de) 2006-06-08
AU1986092A (en) 1993-01-25
NL300198I1 (nl) 2005-08-01
NO2017045I1 (no) 2017-08-23
JP3130935B2 (ja) 2001-01-31
AU672361B2 (en) 1996-10-03
NO2005018I1 (no) 2005-09-26
NO934798D0 (no) 1993-12-23
NO2005018I2 (no) 2008-02-11
DE69228813D1 (de) 1999-05-06
PT100619B (pt) 1999-07-30
JPH06508628A (ja) 1994-09-29
DK0591275T3 (da) 1999-10-11
IE922024A1 (en) 1992-12-30
LU91180I2 (fr) 2005-09-06
HK1008662A1 (en) 1999-05-14
WO1993000080A1 (en) 1993-01-07
PT100619A (pt) 1994-01-31
EP0591275A1 (de) 1994-04-13
ES2129448T3 (es) 1999-06-16
GR3029841T3 (en) 1999-07-30
DE122005000032I1 (de) 2005-09-29
NO934798L (no) 1993-12-23
CA2072047C (en) 2003-06-10

Similar Documents

Publication Publication Date Title
NO2017045I1 (no) Farmasøøytisk preparat inneholdende 2-(2-nitro-4-ifluormetylbenzoyl)-1,3-cykloheksandion eller et farmasøytisk godtagbart salt derav
ATE443043T1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
DE59407237D1 (de) Nitrato-aminosäure-disulfide zur therapie von erkrankungen des herz-kreislauf-systems
ATE309797T1 (de) Ibuprofen und diphenhydramin enthaltende zusammensetzungen und deren verwendung zur behandlung von schlafstörungen
DE60330485D1 (de) Zur behandlung von diabetes
ATE321548T1 (de) Verwendung von statin zur behandlung von hauterkrankungen
ATE238792T1 (de) Verwendung von makroliden zur behandlung von glaukom
DE60323765D1 (de) Inhibitoren der 17 beta-hydroxysteroiddehydrogenase des typs 3 zur behandlung androgenabhängiger krankheiten
RU94044454A (ru) Ингибитор аутоимунных заболеваний
NO166939C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive carboxylsyrederivater.
ATE334120T1 (de) Pharmazeutische zusammensetzungen zur vorbeugung und behandlung von störungen des zentralnervensystems
DE69420776D1 (de) Idebenone-haltige Zusammensetzungen zur Behandlung von M. Alzheimer
WO2002100836A8 (en) Compounds, compositions and methods for modulating beta-amyloid production
ATE192923T1 (de) Verwendung von boswelliasäure zur behandlung von hirntumoren
ATE499933T1 (de) Verwendung von betain zur behandlung von claudicatio intermittens
MX9300203A (es) Compuestos policiclicos disubstituidos y composicion farmaceutica que los contiene.
DE59101267D1 (de) N-Alkyl-N-(meth)acryloyloxyalkylcarboxamide aromatischer Carbonsäuren und aromatischer Carbonsäureanhydride sowie Adhäsive enthaltend diese Verbindungen.
ES2110057T3 (es) Composicion medicinal que contiene tcf-ii.
DE69626916D1 (de) Sertralin zur Behandlung von Post-Myocard-Infarkt-Patienten
ATE190484T1 (de) Arzneimittel zur behandlung von durch babesia verursachten protozoeninfektionen
DE69928814D1 (de) Verwendung von tgf-beta inhibitoren zur behandlung von cerebralen krankheiten
DE69421705D1 (de) Verwendung von Efaroxan und dessen Derivaten zur Herstellung eines Arzneimittels zur Behandlung neurogenerativer Erkrankungen
DE69832796D1 (de) Verwendung von mizolastine zur herstellung eines arzneimittels zur behandlung von entzündungen
DE69715227D1 (de) Verwendung von kalzium dobesilat zur herstellung eines arzneimittels zur behandlung von embryonaler zurückgebliebenheit
UA30332A (uk) Спосіб лікування псоріазу